Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 61 entries
Sorted by: Best Match Show Resources per page
Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).

Oncoimmunology

Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH.
PMID: 26587318
Oncoimmunology. 2015 Aug 07;4(12):e1049804. doi: 10.1080/2162402X.2015.1049804. eCollection 2015 Dec.

Molecular and immune classifications powerfully predict cancer patient's survival and response to therapies. We herein describe the immune tumor microenvironment of molecular subgroups of colorectal and renal cell cancers, revealing a strong correlation between tumor subtypes and distinct immune...

Cite
Becht E, Giraldo NA, Beuselinck B, et al. Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncoimmunology. 2015;4(12):e1049804doi: 10.1080/2162402X.2015.1049804.
Becht, E., Giraldo, N. A., Beuselinck, B., Job, S., Marisa, L., Vano, Y., Oudard, S., Zucman-Rossi, J., Laurent-Puig, P., Sautès-Fridman, C., de Reyniès, A., & Fridman, W. H. (2015). Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncoimmunology, 4(12), e1049804. https://doi.org/10.1080/2162402X.2015.1049804
Becht, Etienne, et al. "Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)." Oncoimmunology vol. 4,12 (2015): e1049804. doi: https://doi.org/10.1080/2162402X.2015.1049804
Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH. Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncoimmunology. 2015 Aug 07;4(12):e1049804. doi: 10.1080/2162402X.2015.1049804. eCollection 2015 Dec. PMID: 26587318; PMCID: PMC4635888.
Copy Download .nbib Format: NLM
Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial.

Oncotarget

Pugh S, Thiébaut R, Bridgewater J, Grisoni ML, Moutasim K, Rousseau F, Thomas GJ, Griffiths G, Liebaert F, Primrose J, Laurent-Puig P.
PMID: 29212194
Oncotarget. 2017 Sep 27;8(55):93856-93866. doi: 10.18632/oncotarget.21291. eCollection 2017 Nov 07.

BACKGROUND: High miR-31-3p expression is associated with inferior outcomes in KRAS wild-type (WT) advanced colorectal cancer patients treated with anti-EGFR therapy. This study evaluated miR-31-3p expression in patients with operable colorectal liver metastases (LM) enrolled in the New EPOC...

Cite
Pugh S, Thiébaut R, Bridgewater J, et al. Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. Oncotarget. 2017;8(55):93856-93866doi: 10.18632/oncotarget.21291.
Pugh, S., Thiébaut, R., Bridgewater, J., Grisoni, M. L., Moutasim, K., Rousseau, F., Thomas, G. J., Griffiths, G., Liebaert, F., Primrose, J., & Laurent-Puig, P. (2017). Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. Oncotarget, 8(55), 93856-93866. https://doi.org/10.18632/oncotarget.21291
Pugh, Siân, et al. "Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial." Oncotarget vol. 8,55 (2017): 93856-93866. doi: https://doi.org/10.18632/oncotarget.21291
Pugh S, Thiébaut R, Bridgewater J, Grisoni ML, Moutasim K, Rousseau F, Thomas GJ, Griffiths G, Liebaert F, Primrose J, Laurent-Puig P. Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. Oncotarget. 2017 Sep 27;8(55):93856-93866. doi: 10.18632/oncotarget.21291. eCollection 2017 Nov 07. PMID: 29212194; PMCID: PMC5706840.
Copy Download .nbib Format: NLM
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Oncoimmunology

Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.
PMID: 28507793
Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.

Anaplastic lymphoma kinase (ALK) inhibitors have been successfully developed for non-small cell lung carcinoma (NSCLC) displaying chromosomal rearrangements of the

Cite
Roussel H, De Guillebon E, Biard L, et al. Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. Oncoimmunology. 2017;6(4):e1286437doi: 10.1080/2162402X.2017.1286437.
Roussel, H., De Guillebon, E., Biard, L., Mandavit, M., Gibault, L., Fabre, E., Antoine, M., Hofman, P., Beau-Faller, M., Blons, H., Danel, C., Barthes, F. L. P., Gey, A., Granier, C., Wislez, M., Laurent-Puig, P., Oudard, S., Bruneval, P., Badoual, C., Cadranel, J., & Tartour, E. (2017). Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. Oncoimmunology, 6(4), e1286437. https://doi.org/10.1080/2162402X.2017.1286437
Roussel, Hélène, et al. "Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy." Oncoimmunology vol. 6,4 (2017): e1286437. doi: https://doi.org/10.1080/2162402X.2017.1286437
Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E. Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017. PMID: 28507793; PMCID: PMC5414864.
Copy Download .nbib Format: NLM
Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer.

Cancers

Legras A, Pécuchet N, Imbeaud S, Pallier K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F, Laurent-Puig P, Blons H.
PMID: 28771186
Cancers (Basel). 2017 Aug 03;9(8). doi: 10.3390/cancers9080101.

Despite major advances, non-small cell lung cancer (NSCLC) remains the major cause of cancer-related death in developed countries. Metastasis and drug resistance are the main factors contributing to relapse and death. Epithelial-to-mesenchymal transition (EMT) is a complex molecular and...

Cite
Legras A, Pécuchet N, Imbeaud S, et al. Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. Cancers (Basel). 2017;9(8)doi: 10.3390/cancers9080101.
Legras, A., Pécuchet, N., Imbeaud, S., Pallier, K., Didelot, A., Roussel, H., Gibault, L., Fabre, E., Le Pimpec-Barthes, F., Laurent-Puig, P., & Blons, H. (2017). Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. Cancers, 9(8), . https://doi.org/10.3390/cancers9080101
Legras, Antoine, et al. "Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer." Cancers vol. 9,8 (2017). doi: https://doi.org/10.3390/cancers9080101
Legras A, Pécuchet N, Imbeaud S, Pallier K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F, Laurent-Puig P, Blons H. Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. Cancers (Basel). 2017 Aug 03;9(8). doi: 10.3390/cancers9080101. PMID: 28771186; PMCID: PMC5575604.
Copy Download .nbib Format: NLM
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.

Journal of thoracic disease

Blons H, Garinet S, Laurent-Puig P, Oudart JB.
PMID: 30775025
J Thorac Dis. 2019 Jan;11:S25-S36. doi: 10.21037/jtd.2018.12.48.

Immunotherapy represents one of the most promising therapeutic approaches in lung cancer, however 50% of lung cancer patients will not respond to this treatment, while others will have transitory or durable responses. Because side effects may be life threatening...

Cite
Blons H, Garinet S, Laurent-Puig P, et al. Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. J Thorac Dis. 2019;11:S25-S36doi: 10.21037/jtd.2018.12.48.
Blons, H., Garinet, S., Laurent-Puig, P., & Oudart, J. B. (2019). Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. Journal of thoracic disease, 11S25-S36. https://doi.org/10.21037/jtd.2018.12.48
Blons, Hélène, et al. "Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update." Journal of thoracic disease vol. 11 (2019): S25-S36. doi: https://doi.org/10.21037/jtd.2018.12.48
Blons H, Garinet S, Laurent-Puig P, Oudart JB. Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. J Thorac Dis. 2019 Jan;11:S25-S36. doi: 10.21037/jtd.2018.12.48. PMID: 30775025; PMCID: PMC6353739.
Copy Download .nbib Format: NLM
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Gallois C, Emile JF, Kim S, Monterymard C, Gilabert M, Bez J, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Coriat R, Legoux JL, Hautefeuille V, Phelip JM, Lecomte T, Sokol H, Capron C, Randrian V, Lepage C, Lomenie N, Kurtz C, Taieb J, Tougeron D.
PMID: 34215534
Dig Liver Dis. 2021 Oct;53(10):1254-1259. doi: 10.1016/j.dld.2021.06.009. Epub 2021 Jun 30.

Pembrolizumab, a PD1 immune checkpoint inhibitor (ICI), was recently reported to be very effective in patients with microsatellite instable/deficient mismatch repair metastatic colorectal cancer (MSI/dMMR mCRC), unlike patients with microsatellite stable/proficient MMR (MSS/pMMR) mCRC, in whom ICIs are generally...

Cite
Gallois C, Emile JF, Kim S, et al. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Dig Liver Dis. 2021;53(10):1254-1259doi: 10.1016/j.dld.2021.06.009.
Gallois, C., Emile, J. F., Kim, S., Monterymard, C., Gilabert, M., Bez, J., Lièvre, A., Dahan, L., Laurent-Puig, P., Mineur, L., Coriat, R., Legoux, J. L., Hautefeuille, V., Phelip, J. M., Lecomte, T., Sokol, H., Capron, C., Randrian, V., Lepage, C., Lomenie, N., Kurtz, C., Taieb, J., & Tougeron, D. (2021). Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53(10), 1254-1259. https://doi.org/10.1016/j.dld.2021.06.009
Gallois, Claire, et al. "Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial." Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver vol. 53,10 (2021): 1254-1259. doi: https://doi.org/10.1016/j.dld.2021.06.009
Gallois C, Emile JF, Kim S, Monterymard C, Gilabert M, Bez J, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Coriat R, Legoux JL, Hautefeuille V, Phelip JM, Lecomte T, Sokol H, Capron C, Randrian V, Lepage C, Lomenie N, Kurtz C, Taieb J, Tougeron D. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Dig Liver Dis. 2021 Oct;53(10):1254-1259. doi: 10.1016/j.dld.2021.06.009. Epub 2021 Jun 30. PMID: 34215534.
Copy Download .nbib Format: NLM
An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution.

Cell death and differentiation

Lindner AU, Salvucci M, McDonough E, Cho S, Stachtea X, O'Connell EP, Corwin AD, Santamaria-Pang A, Carberry S, Fichtner M, Van Schaeybroeck S, Laurent-Puig P, Burke JP, McNamara DA, Lawler M, Sood A, Graf JF, Rehm M, Dunne PD, Longley DB, Ginty F, Prehn JHM.
PMID: 34754079
Cell Death Differ. 2021 Nov 09; doi: 10.1038/s41418-021-00895-9. Epub 2021 Nov 09.

Cancer cells' ability to inhibit apoptosis is key to malignant transformation and limits response to therapy. Here, we performed multiplexed immunofluorescence analysis on tissue microarrays with 373 cores from 168 patients, segmentation of 2.4 million individual cells, and quantification...

Cite
Lindner AU, Salvucci M, McDonough E, et al. An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. Cell Death Differ. 2021;doi: 10.1038/s41418-021-00895-9.
Lindner, A. U., Salvucci, M., McDonough, E., Cho, S., Stachtea, X., O'Connell, E. P., Corwin, A. D., Santamaria-Pang, A., Carberry, S., Fichtner, M., Van Schaeybroeck, S., Laurent-Puig, P., Burke, J. P., McNamara, D. A., Lawler, M., Sood, A., Graf, J. F., Rehm, M., Dunne, P. D., Longley, D. B., Ginty, F., & Prehn, J. H. M. (2021). An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. Cell death and differentiation, . https://doi.org/10.1038/s41418-021-00895-9
Lindner, Andreas Ulrich, et al. "An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution." Cell death and differentiation vol. (2021). doi: https://doi.org/10.1038/s41418-021-00895-9
Lindner AU, Salvucci M, McDonough E, Cho S, Stachtea X, O'Connell EP, Corwin AD, Santamaria-Pang A, Carberry S, Fichtner M, Van Schaeybroeck S, Laurent-Puig P, Burke JP, McNamara DA, Lawler M, Sood A, Graf JF, Rehm M, Dunne PD, Longley DB, Ginty F, Prehn JHM. An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. Cell Death Differ. 2021 Nov 09; doi: 10.1038/s41418-021-00895-9. Epub 2021 Nov 09. PMID: 34754079.
Copy Download .nbib Format: NLM
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a .

Clinical cancer research : an official journal of the American Association for Cancer Research

Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M, Egreteau J, Bouche O, Mulot C, Hormigos K, Chaba K, Mazard T, de Gramont A, Vernerey D, André T, Laurent-Puig P.
PMID: 34083233
Clin Cancer Res. 2021 Oct 15;27(20):5638-5646. doi: 10.1158/1078-0432.CCR-21-0271. Epub 2021 Jun 03.

PURPOSE: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients randomized in the phase III IDEA-France trial.EXPERIMENTAL DESIGN: ctDNA was tested for RESULTS: Of 2,010 randomized...

Cite
Taieb J, Taly V, Henriques J, et al. Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a . Clin Cancer Res. 2021;27(20):5638-5646doi: 10.1158/1078-0432.CCR-21-0271.
Taieb, J., Taly, V., Henriques, J., Bourreau, C., Mineur, L., Bennouna, J., Desrame, J., Louvet, C., Lepere, C., Mabro, M., Egreteau, J., Bouche, O., Mulot, C., Hormigos, K., Chaba, K., Mazard, T., de Gramont, A., Vernerey, D., André, T., & Laurent-Puig, P. (2021). Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(20), 5638-5646. https://doi.org/10.1158/1078-0432.CCR-21-0271
Taieb, Julien, et al. "Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,20 (2021): 5638-5646. doi: https://doi.org/10.1158/1078-0432.CCR-21-0271
Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M, Egreteau J, Bouche O, Mulot C, Hormigos K, Chaba K, Mazard T, de Gramont A, Vernerey D, André T, Laurent-Puig P. Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a . Clin Cancer Res. 2021 Oct 15;27(20):5638-5646. doi: 10.1158/1078-0432.CCR-21-0271. Epub 2021 Jun 03. PMID: 34083233.
Copy Download .nbib Format: NLM
Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.

Cell death & disease

Deng J, Tian AL, Pan H, Sauvat A, Leduc M, Liu P, Zhao L, Zhang S, Chen H, Taly V, Laurent-Puig P, Senovilla L, Li Y, Kroemer G, Kepp O.
PMID: 34675191
Cell Death Dis. 2021 Oct 21;12(11):978. doi: 10.1038/s41419-021-04270-x.

Colorectal cancers (CRC) can be classified into four consensus molecular subtypes (CMS), among which CMS1 has the best prognosis, contrasting with CMS4 that has the worst outcome. CMS4 CRC is notoriously resistant against therapeutic interventions, as demonstrated by preclinical...

Cite
Deng J, Tian AL, Pan H, et al. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell Death Dis. 2021;12(11):978doi: 10.1038/s41419-021-04270-x.
Deng, J., Tian, A. L., Pan, H., Sauvat, A., Leduc, M., Liu, P., Zhao, L., Zhang, S., Chen, H., Taly, V., Laurent-Puig, P., Senovilla, L., Li, Y., Kroemer, G., & Kepp, O. (2021). Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell death & disease, 12(11), 978. https://doi.org/10.1038/s41419-021-04270-x
Deng, Jiayin, et al. "Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype." Cell death & disease vol. 12,11 (2021): 978. doi: https://doi.org/10.1038/s41419-021-04270-x
Deng J, Tian AL, Pan H, Sauvat A, Leduc M, Liu P, Zhao L, Zhang S, Chen H, Taly V, Laurent-Puig P, Senovilla L, Li Y, Kroemer G, Kepp O. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell Death Dis. 2021 Oct 21;12(11):978. doi: 10.1038/s41419-021-04270-x. PMID: 34675191; PMCID: PMC8531384.
Copy Download .nbib Format: NLM
hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status.

Cancers

Raffenne J, Nicolle R, Puleo F, Le Corre D, Boyez C, Marechal R, Emile JF, Demetter P, Bardier A, Laurent-Puig P, de Mestier L, Paradis V, Couvelard A, VanLathem JL, MacKey JR, Bachet JB, Svrcek M, Cros J.
PMID: 31752123
Cancers (Basel). 2019 Nov 18;11(11). doi: 10.3390/cancers11111808.

Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC). Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). It was therefore proposed as a potential predictive biomarker of...

Cite
Raffenne J, Nicolle R, Puleo F, et al. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Cancers (Basel). 2019;11(11)doi: 10.3390/cancers11111808.
Raffenne, J., Nicolle, R., Puleo, F., Le Corre, D., Boyez, C., Marechal, R., Emile, J. F., Demetter, P., Bardier, A., Laurent-Puig, P., de Mestier, L., Paradis, V., Couvelard, A., VanLathem, J. L., MacKey, J. R., Bachet, J. B., Svrcek, M., & Cros, J. (2019). hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Cancers, 11(11), . https://doi.org/10.3390/cancers11111808
Raffenne, Jerome, et al. "hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status." Cancers vol. 11,11 (2019). doi: https://doi.org/10.3390/cancers11111808
Raffenne J, Nicolle R, Puleo F, Le Corre D, Boyez C, Marechal R, Emile JF, Demetter P, Bardier A, Laurent-Puig P, de Mestier L, Paradis V, Couvelard A, VanLathem JL, MacKey JR, Bachet JB, Svrcek M, Cros J. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Cancers (Basel). 2019 Nov 18;11(11). doi: 10.3390/cancers11111808. PMID: 31752123; PMCID: PMC6896053.
Copy Download .nbib Format: NLM
Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Case-Control Studies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Zidane M, Truong T, Lesueur F, Xhaard C, Cordina-Duverger E, Boland A, Blanché H, Ory C, Chevillard S, Deleuze JF, Souchard V, Ren Y, Zemmache MZ, Canale S, Borson-Chazot F, Schvartz C, Mariné Barjoan E, Guizard AV, Laurent-Puig P, Mulot C, Guibon J, Karimi M, Schlumberger M, Adjadj E, Rubino C, Guenel P, Cazier JB, de Vathaire F.
PMID: 33827984
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1208-1217. doi: 10.1158/1055-9965.EPI-20-1142. Epub 2021 Apr 07.

BACKGROUND: Given the increased use and diversity of diagnostic procedures, it is important to understand genetic susceptibility to radiation-induced thyroid cancer.METHODS: On the basis of self-declared diagnostic radiology examination records in addition to existing literature, we estimated the radiation...

Cite
Zidane M, Truong T, Lesueur F, et al. Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Case-Control Studies. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1208-1217doi: 10.1158/1055-9965.EPI-20-1142.
Zidane, M., Truong, T., Lesueur, F., Xhaard, C., Cordina-Duverger, E., Boland, A., Blanché, H., Ory, C., Chevillard, S., Deleuze, J. F., Souchard, V., Ren, Y., Zemmache, M. Z., Canale, S., Borson-Chazot, F., Schvartz, C., Mariné Barjoan, E., Guizard, A. V., Laurent-Puig, P., Mulot, C., Guibon, J., Karimi, M., Schlumberger, M., Adjadj, E., Rubino, C., Guenel, P., Cazier, J. B., & de Vathaire, F. (2021). Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Case-Control Studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(6), 1208-1217. https://doi.org/10.1158/1055-9965.EPI-20-1142
Zidane, Monia, et al. "Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Case-Control Studies." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,6 (2021): 1208-1217. doi: https://doi.org/10.1158/1055-9965.EPI-20-1142
Zidane M, Truong T, Lesueur F, Xhaard C, Cordina-Duverger E, Boland A, Blanché H, Ory C, Chevillard S, Deleuze JF, Souchard V, Ren Y, Zemmache MZ, Canale S, Borson-Chazot F, Schvartz C, Mariné Barjoan E, Guizard AV, Laurent-Puig P, Mulot C, Guibon J, Karimi M, Schlumberger M, Adjadj E, Rubino C, Guenel P, Cazier JB, de Vathaire F. Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Case-Control Studies. Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1208-1217. doi: 10.1158/1055-9965.EPI-20-1142. Epub 2021 Apr 07. PMID: 33827984.
Copy Download .nbib Format: NLM
The Cellular Prion Protein and the Hallmarks of Cancer.

Cancers

Mouillet-Richard S, Ghazi A, Laurent-Puig P.
PMID: 34638517
Cancers (Basel). 2021 Oct 08;13(19). doi: 10.3390/cancers13195032.

Beyond its causal involvement in a group of neurodegenerative diseases known as Transmissible Spongiform Encephalopathies, the cellular prion protein PrP

Cite
Mouillet-Richard S, Ghazi A, Laurent-Puig P. The Cellular Prion Protein and the Hallmarks of Cancer. Cancers (Basel). 2021;13(19)doi: 10.3390/cancers13195032.
Mouillet-Richard, S., Ghazi, A., & Laurent-Puig, P. (2021). The Cellular Prion Protein and the Hallmarks of Cancer. Cancers, 13(19), . https://doi.org/10.3390/cancers13195032
Mouillet-Richard, Sophie, et al. "The Cellular Prion Protein and the Hallmarks of Cancer." Cancers vol. 13,19 (2021). doi: https://doi.org/10.3390/cancers13195032
Mouillet-Richard S, Ghazi A, Laurent-Puig P. The Cellular Prion Protein and the Hallmarks of Cancer. Cancers (Basel). 2021 Oct 08;13(19). doi: 10.3390/cancers13195032. PMID: 34638517; PMCID: PMC8508458.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 61 entries